End-of-day quote
Other stock markets
|
||
- USD | - |
2014 | Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug | RE |
2014 | Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Karen Rogers
PRN | Corporate Officer/Principal | - | - |
Sales & Marketing | - | - | |
Corporate Officer/Principal | - | 31/12/96 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 31/08/06 | |
Director/Board Member | 70 | 24/09/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 76,295,299 | 75,907,820 ( 99.49 %) | 0 | 99.49 % |
Company contact information
Cubist Pharmaceuticals LLC
155 Federal Street Suite 700
02110, Boston
+781-860-8660
http://www.cubist.comSector
1st Jan change | Capi. | |
---|---|---|
-2.35% | 89.33B | |
+4.08% | 41.19B | |
-15.09% | 31.87B | |
+53.68% | 24.52B | |
-15.13% | 15.68B | |
-8.63% | 12.34B | |
-40.39% | 12.23B | |
+6.22% | 8.83B | |
-6.43% | 8.28B |
- Stock Market
- Equities
- Stock
- Company Cubist Pharmaceuticals Inc